Acquired Thrombotic Thrombocytopenic Purpura (aTTP) (DBCOND0120680)

Identifiers

Synonyms

Acquired Thrombotic Thrombocytopenic Purpura / Acquired thrombotic thrombocytopenic purpura (disorder)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Caplacizumab	A von Willebrand factor (vWF)-directed antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP).	von Willebrand factortarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05876221	Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura	Caplacizumab	Not Available	Not Available	recruiting
NCT04720261	Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP	Caplacizumab	treatment	2	unknown_status
NCT04985318	Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP	Caplacizumab	Not Available	Not Available	recruiting
NCT02553317	Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura	Caplacizumab	treatment	3	completed
NCT04021173	A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)	Anfibatide	treatment	2	unknown_status
NCT05262881	A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)	No drug interventions	Not Available	Not Available	unknown_status
NCT01151423	Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)	Caplacizumab	treatment	2	completed
NCT02878603	Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)	Caplacizumab	treatment	3	completed
NCT05135442	Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP	Bortezomib Bortezomib D-mannitol	treatment	4	not_yet_recruiting
NCT05046717	Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura	No drug interventions	Not Available	Not Available	recruiting
NCT03922308	Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)	Apadamtase alfa	treatment	2	completed